Stephens Investment Management Group LLC Boosts Stock Position in Repligen Corporation $RGEN

Posted by on Jul 5th, 2026

Stephens Investment Management Group LLC increased its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 15.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 755,571 shares of the biotechnology company’s stock after purchasing an additional 98,460 shares during the quarter. Repligen makes up approximately 1.2% of Stephens Investment Management Group LLC’s holdings, making the stock its 15th largest holding. Stephens Investment Management Group LLC’s holdings in Repligen were worth $89,021,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of RGEN. United Capital Financial Advisors LLC purchased a new stake in Repligen in the 3rd quarter worth approximately $368,387,000. Opti Capital Management LP bought a new stake in shares of Repligen in the 4th quarter worth approximately $2,399,209,000. Wasatch Advisors LP purchased a new position in shares of Repligen during the first quarter valued at approximately $146,513,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Repligen during the fourth quarter valued at approximately $199,176,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after acquiring an additional 1,091,683 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of Repligen stock opened at $142.40 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company has a 50-day moving average of $123.84 and a 200 day moving average of $134.79. The firm has a market cap of $8.03 billion, a price-to-earnings ratio of 158.22, a PEG ratio of 2.74 and a beta of 1.06. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the company posted $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

RGEN has been the subject of a number of research analyst reports. HSBC dropped their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Wolfe Research assumed coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective for the company. Barclays lifted their price objective on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. HC Wainwright increased their target price on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Finally, JPMorgan Chase & Co. lowered their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Get Our Latest Stock Report on RGEN

Repligen Profile

(Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Featured Articles

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.